Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPSE | Q9Y251 | 2/20 | 0.58 |
| ▸ | FGF1 | P05230 | 1/20 | 0.58 |
| ▸ | FGF2 | P09038 | 1/20 | 0.58 |
| ▸ | VEGFA | P15692 | 1/20 | 0.58 |
| ▸ | MDK | P21741 | 4/20 | 0.58 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.42 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.42 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.42 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.41 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.41 |
| ▸ | PLCD1 | P51178 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.39 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23126071 | 0.98 | HPSE (0.56) | HPSEFGF1FGF2VEGFAMDK | |
| SCHEMBL20520078 | 0.96 | MDK (0.64) | HPSEFGF1FGF2VEGFAMDK | |
| SCHEMBL20520177 | 0.96 | MDK (0.64) | HPSEFGF1FGF2VEGFAMDK | |
| SCHEMBL23126113 | 0.95 | MDK (0.54) | HPSEFGF1FGF2VEGFAMDK | |
| SCHEMBL23126139 | 0.95 | HPSE (0.56) | HPSEFGF1FGF2VEGFAMDK | |
| SCHEMBL20519908 | 0.95 | HPSE (0.56) | HPSEFGF1FGF2VEGFAMDK | |
| SCHEMBL24067597 | 0.95 | HPSE (0.56) | HPSEFGF1FGF2VEGFAMDK | |
| SCHEMBL24067582 | 0.95 | HPSE (0.56) | HPSEFGF1FGF2VEGFAMDK | |
| SCHEMBL24067580 | 0.95 | HPSE (0.56) | HPSEFGF1FGF2VEGFAMDK | |
| SCHEMBL20519925 | 0.95 | HPSE (0.56) | HPSEFGF1FGF2VEGFAMDK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210369850-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | Centauri Therapeutics Limited (GB/GB) (GB) | 2021-12-02 | — | — | US | disclosed |
| US-10953100-B2 | Compounds and therapeutic uses thereof | CENTUARI THERAPEUTICS LIMITED (GB/GB) (GB) | 2021-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210369850-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | CD47, MYD88, NFATC1 | HPSE 762/4885FGF1 4232/4885FGF2 4081/4885 |
| US-10953100-B2 | Compounds and therapeutic uses thereof | CD47, MYD88, NFATC1 | HPSE 762/4885FGF1 4232/4885FGF2 4081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.